JP2017502967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502967A5 JP2017502967A5 JP2016544133A JP2016544133A JP2017502967A5 JP 2017502967 A5 JP2017502967 A5 JP 2017502967A5 JP 2016544133 A JP2016544133 A JP 2016544133A JP 2016544133 A JP2016544133 A JP 2016544133A JP 2017502967 A5 JP2017502967 A5 JP 2017502967A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- dutpase
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 47
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 claims description 35
- 108010011219 dUTP pyrophosphatase Proteins 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 229940035893 uracil Drugs 0.000 claims description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- -1 substituted Chemical class 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 101000904652 Homo sapiens Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Proteins 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 125000005549 heteroarylene group Chemical group 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000013068 control sample Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 0 Cc1ccc(*)c(*)c1 Chemical compound Cc1ccc(*)c(*)c1 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 229950009822 gimeracil Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 238000009095 third-line therapy Methods 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923534P | 2014-01-03 | 2014-01-03 | |
| US61/923,534 | 2014-01-03 | ||
| PCT/US2015/010059 WO2015103489A1 (en) | 2014-01-03 | 2015-01-02 | Heteroatom containing deoxyuridine triphosphatase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502967A JP2017502967A (ja) | 2017-01-26 |
| JP2017502967A5 true JP2017502967A5 (enExample) | 2018-02-08 |
| JP6513095B2 JP6513095B2 (ja) | 2019-05-15 |
Family
ID=53494059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544133A Active JP6513095B2 (ja) | 2014-01-03 | 2015-01-02 | ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9790214B2 (enExample) |
| EP (1) | EP3089964B1 (enExample) |
| JP (1) | JP6513095B2 (enExample) |
| CN (1) | CN106061952B (enExample) |
| CA (1) | CA2935717C (enExample) |
| IL (1) | IL246545B (enExample) |
| WO (1) | WO2015103489A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189478B (zh) | 2013-01-07 | 2019-10-22 | 南加州大学 | 脱氧尿苷三磷酸酶抑制剂 |
| EP3089964B1 (en) | 2014-01-03 | 2021-02-24 | University Of Southern California | Heteroatom-containing deoxyuridine triphosphatase inhibitors |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| JP6836589B2 (ja) | 2015-07-08 | 2021-03-03 | シーブイ６ セラピューティクス （エヌアイ） リミテッド | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787766A (fr) | 1971-08-21 | 1973-02-19 | Merck Patent Gmbh | Imides d'acide glutarique et leur procede de preparation |
| US4304715A (en) | 1979-06-08 | 1981-12-08 | Derek Hudson | Enkephalin analogues |
| JPS5839672A (ja) | 1981-09-03 | 1983-03-08 | Chugai Pharmaceut Co Ltd | ウラシル誘導体 |
| JPH0674251B2 (ja) | 1986-02-07 | 1994-09-21 | 全薬工業株式▲会▼社 | ビス−ジオキソピペラジン誘導体 |
| JPS63101361A (ja) | 1986-09-08 | 1988-05-06 | ブリティッシュ・テクノロジー・グループ・リミテッド | ジオキソピペリジン誘導体を含有する不安解消組成物 |
| FR2644786B1 (fr) * | 1989-03-21 | 1993-12-31 | Adir Cie | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
| US5962246A (en) | 1996-03-29 | 1999-10-05 | The University Of Medicine And Dentistry Of New Jersey | dUTPase, its isoforms, and diagnostic and other uses |
| JPH09286786A (ja) | 1996-04-18 | 1997-11-04 | Nippon Paper Ind Co Ltd | ピリミジン誘導体及びその抗腫瘍剤としての用途 |
| US6054470A (en) | 1997-12-18 | 2000-04-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Src family SH2 domain inhibitors |
| CA2366264A1 (en) | 1999-04-02 | 2000-10-12 | Bristol-Myers Squibb Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase |
| DE10002509A1 (de) | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| JP2002284686A (ja) | 2001-03-28 | 2002-10-03 | Sankyo Co Ltd | スルホンアミド化合物を含有する医薬組成物 |
| JP2004527535A (ja) * | 2001-04-11 | 2004-09-09 | クイーンズ ユニバーシティ アット キングストン | 抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物 |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
| EP1848433A2 (en) | 2005-01-25 | 2007-10-31 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| WO2006135763A2 (en) | 2005-06-09 | 2006-12-21 | The Johns Hopkins University | Inhibitors of dna repair enzymes and methods of use thereof |
| NZ573793A (en) | 2006-07-24 | 2012-01-12 | Korea Res Inst Chem Tech | Hiv reverse transcriptase inhibitors |
| EP1939186A1 (en) | 2006-12-22 | 2008-07-02 | Sulfidris S.r.l. | 5-Fluorouracil derivatives and their use for the treatment of cancer |
| WO2009074575A2 (en) | 2007-12-10 | 2009-06-18 | Novartis Ag | Organic compounds |
| KR101384940B1 (ko) * | 2008-06-03 | 2014-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 인간 데옥시우리딘 트리포스파타아제 저해 활성을 갖는 신규 우라실 화합물 또는 그 염 |
| WO2010025308A2 (en) | 2008-08-27 | 2010-03-04 | Universtiy Of Southern California | Inhibitors of dutpase |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
| JP2013032293A (ja) | 2009-11-30 | 2013-02-14 | Taiho Yakuhin Kogyo Kk | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 |
| TWI466870B (zh) | 2009-11-30 | 2015-01-01 | Taiho Pharmaceutical Co Ltd | Anti - tumor efficacy enhancer |
| JP2013047189A (ja) | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| PL2508158T3 (pl) | 2011-04-04 | 2014-11-28 | Arjo Hospital Equipment Ab | Urządzenie wciągnikowe |
| CN105189478B (zh) | 2013-01-07 | 2019-10-22 | 南加州大学 | 脱氧尿苷三磷酸酶抑制剂 |
| EP3089964B1 (en) | 2014-01-03 | 2021-02-24 | University Of Southern California | Heteroatom-containing deoxyuridine triphosphatase inhibitors |
| EP3290038A4 (en) | 2015-04-30 | 2018-12-26 | Taiho Pharmaceutical Co., Ltd. | Agent for alleviating adverse reaction to antitumor drug |
| US10259792B2 (en) | 2015-05-01 | 2019-04-16 | Taiho Pharmaceutical Co., Ltd. | Crystal of uracil compound |
| JP6836589B2 (ja) | 2015-07-08 | 2021-03-03 | シーブイ６ セラピューティクス （エヌアイ） リミテッド | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
-
2015
- 2015-01-02 EP EP15733304.8A patent/EP3089964B1/en active Active
- 2015-01-02 US US15/109,616 patent/US9790214B2/en active Active
- 2015-01-02 CA CA2935717A patent/CA2935717C/en active Active
- 2015-01-02 WO PCT/US2015/010059 patent/WO2015103489A1/en not_active Ceased
- 2015-01-02 JP JP2016544133A patent/JP6513095B2/ja active Active
- 2015-01-02 CN CN201580012064.6A patent/CN106061952B/zh active Active
-
2016
- 2016-06-30 IL IL246545A patent/IL246545B/en active IP Right Grant
-
2017
- 2017-09-28 US US15/719,165 patent/US10457673B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502967A5 (enExample) | ||
| JP2016505621A5 (enExample) | ||
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| US20250115563A1 (en) | Modulators of the integrated stress pathway | |
| JP2019518741A5 (enExample) | ||
| JP7378394B2 (ja) | Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤 | |
| WO2023140846A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
| RS65214B1 (sr) | Modulatori integrisanog puta stresa | |
| KR20190022520A (ko) | Hdac 억제제 및 pd-l1 억제제의 병용 요법 | |
| JP2017528524A5 (enExample) | ||
| RU2006109599A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| US20250339416A1 (en) | Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug | |
| CA2976766A1 (en) | Formylated n-heterocyclic derivatives as fgfr4 inhibitors | |
| RU2017109355A (ru) | Гетероциклические соединения и их применение | |
| JP2021517146A (ja) | １，２，４−オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ−１のシグナル伝達経路をモジュレートする方法 | |
| EA201892460A1 (ru) | Производные аденина как ингибиторы протеинкиназ | |
| JP2018501261A5 (enExample) | ||
| JP7293108B2 (ja) | Ａｘｌ阻害剤とＥＧＦＲチロシンキナーゼ阻害薬との併用治療法 | |
| BRPI0409374A (pt) | composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico | |
| JP2018531995A5 (enExample) | ||
| JP2018538241A5 (enExample) | ||
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза |